Loading
Latest filing published 04 Aug 2023 for NeuBase Therapeutics, Inc., €1,874.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Dietrich A. Stephan in Ohr Pharmaceutical Inc, where the filings describe the role as chief executive. The record holds 14 filings, for trades running from 12 July 2019 to 2 August 2023.
On the market, this insider has only ever bought: 4 purchases, €122k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 2 share grants and 4 option exercises.
A typical purchase (the median) is worth €29k. On 3 out of 4 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.
On 4 August 2023 came the latest disclosure, an option exercise for €1,874 in Ohr Pharmaceutical Inc. The last insider purchase was made public on 27 April 2021, 2,005 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations